Certara upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Certara (CERT) to Outperform from Market Perform with an unchanged price target of $13. The firm says the company remains a leader in the “broad-based” biosimulation market. It attributes the stock’s underperformance in late 2025 to softer Q3 services bookings, market uncertainty tied to biopharma budget delays, and the recently announced CEO change. The selloff “overplays” Certara’s “durable growth engine,” the analyst tells investors in a research note. Leerink believes the improving market backdrop should drive Certara shares higher.